Julie E Richards1, Jennifer F Bobb2, Amy K Lee2, Gwen T Lapham3, Emily C Williams4, Joseph E Glass5, Evette J Ludman2, Carol Achtmeyer6, Ryan M Caldeiro7, Malia Oliver2, Katharine A Bradley8. 1. Kaiser Permanente Washington Health Research Institute, Seattle USA; Department of Health Services, University of Washington, Seattle USA. Electronic address: Julie.E.Richards@kp.org. 2. Kaiser Permanente Washington Health Research Institute, Seattle USA. 3. Kaiser Permanente Washington Health Research Institute, Seattle USA; Department of Health Services, University of Washington, Seattle USA. 4. Kaiser Permanente Washington Health Research Institute, Seattle USA; Department of Health Services, University of Washington, Seattle USA; VA Puget Sound, Health Services Research and Development Center of Innovation for Veteran-Centered and Value-Driven Care, Seattle, WA USA. 5. Kaiser Permanente Washington Health Research Institute, Seattle USA; Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle USA. 6. Kaiser Permanente Washington Health Research Institute, Seattle USA; VA Puget Sound Health Care System, Center of Excellence in Substance Abuse Treatment and Education, Seattle, USA. 7. Kaiser Permanente Washington, Mental Health and Wellness, Seattle USA. 8. Kaiser Permanente Washington Health Research Institute, Seattle USA; Department of Health Services, University of Washington, Seattle USA; VA Puget Sound, Health Services Research and Development Center of Innovation for Veteran-Centered and Value-Driven Care, Seattle, WA USA; Department of Medicine, University of Washington, Seattle USA.
Abstract
BACKGROUND: This pilot study evaluated whether use of evidence-based implementation strategies to integrate care for cannabis and other drug use into primary care (PC) as part of Behavioral Health Integration (BHI) increased diagnosis and treatment of substance use disorders (SUDs). METHODS: Patients who visited the three pilot PC sites were eligible. Implementation strategies included practice coaching, electronic health record decision support, and performance feedback (3/2015-4/2016). BHI introduced annual screening for past-year cannabis and other drug use, a Symptom Checklist for DSM-5 SUDs, and shared decision-making about treatment options. Main analyses tested whether the proportions of PC patients diagnosed with, and treated for, new cannabis or other drug use disorders (CUDs and DUDs, respectively), differed significantly pre- and post-implementation. RESULTS: Of 39,599 eligible patients, 57% and 59% were screened for cannabis and other drug use, respectively. Among PC patients reporting daily cannabis use (2%) or any drug use (1%), 51% and 37%, respectively, completed an SUD Symptom Checklist. The proportion of PC patients with newly diagnosed CUD increased significantly post-implementation (5 v 17 per 10,000 patients, p < 0.0001), but not other DUDs (10 vs 13 per 10,000, p = 0.24). The proportion treated for newly diagnosed CUDs did not increase post-implementation (1 vs 1 per 10,000, p = 0.80), but did for those treated for newly diagnosed other DUDs (1 vs 3 per 10,000, p = 0.038). CONCLUSIONS: A pilot implementation of BHI to increase routine screening and assessment for SUDs was associated with increased new CUD diagnoses and a small increase in treatment of new other DUDs.
BACKGROUND: This pilot study evaluated whether use of evidence-based implementation strategies to integrate care for cannabis and other drug use into primary care (PC) as part of Behavioral Health Integration (BHI) increased diagnosis and treatment of substance use disorders (SUDs). METHODS:Patients who visited the three pilot PC sites were eligible. Implementation strategies included practice coaching, electronic health record decision support, and performance feedback (3/2015-4/2016). BHI introduced annual screening for past-year cannabis and other drug use, a Symptom Checklist for DSM-5 SUDs, and shared decision-making about treatment options. Main analyses tested whether the proportions of PC patients diagnosed with, and treated for, new cannabis or other drug use disorders (CUDs and DUDs, respectively), differed significantly pre- and post-implementation. RESULTS: Of 39,599 eligible patients, 57% and 59% were screened for cannabis and other drug use, respectively. Among PC patients reporting daily cannabis use (2%) or any drug use (1%), 51% and 37%, respectively, completed an SUD Symptom Checklist. The proportion of PC patients with newly diagnosed CUD increased significantly post-implementation (5 v 17 per 10,000 patients, p < 0.0001), but not other DUDs (10 vs 13 per 10,000, p = 0.24). The proportion treated for newly diagnosed CUDs did not increase post-implementation (1 vs 1 per 10,000, p = 0.80), but did for those treated for newly diagnosed other DUDs (1 vs 3 per 10,000, p = 0.038). CONCLUSIONS: A pilot implementation of BHI to increase routine screening and assessment for SUDs was associated with increased new CUD diagnoses and a small increase in treatment of new other DUDs.
Authors: Gwen T Lapham; Amy K Lee; Ryan M Caldeiro; Dennis McCarty; Kendall C Browne; Denise D Walker; Daniel R Kivlahan; Katharine A Bradley Journal: J Am Board Fam Med Date: 2017 Nov-Dec Impact factor: 2.657
Authors: Katharine A Bradley; Emily C Williams; Carol E Achtmeyer; Bryan Volpp; Bonny J Collins; Daniel R Kivlahan Journal: Am J Manag Care Date: 2006-10 Impact factor: 2.229
Authors: Ruchir N Karmali; G Thomas Ray; Andrea L Rubinstein; Stacy A Sterling; Constance M Weisner; Cynthia I Campbell Journal: Drug Alcohol Depend Date: 2020-02-20 Impact factor: 4.492
Authors: Susanne Hempel; Maria Bolshakova; Barbara J Turner; Jennifer Dinalo; Danielle Rose; Aneesa Motala; Ning Fu; Chase G Clemesha; Lisa Rubenstein; Susan Stockdale Journal: J Gen Intern Med Date: 2022-09-29 Impact factor: 6.473
Authors: Julie E Richards; Elena Kuo; Christine Stewart; Jennifer F Bobb; Kayne D Mettert; Ali Rowhani-Rahbar; Marian E Betz; Rebecca Parrish; Ursula Whiteside; Jennifer M Boggs; Gregory E Simon Journal: JAMA Health Forum Date: 2021-08-06
Authors: Theresa E Matson; Gwen T Lapham; Jennifer F Bobb; Eric Johnson; Julie E Richards; Amy K Lee; Katharine A Bradley; Joseph E Glass Journal: Drug Alcohol Depend Date: 2020-08-08 Impact factor: 4.492
Authors: Lisa A Marsch; Aimee Campbell; Cynthia Campbell; Ching-Hua Chen; Emre Ertin; Udi Ghitza; Chantal Lambert-Harris; Saeed Hassanpour; August F Holtyn; Yih-Ing Hser; Petra Jacobs; Jeffrey D Klausner; Shea Lemley; David Kotz; Andrea Meier; Bethany McLeman; Jennifer McNeely; Varun Mishra; Larissa Mooney; Edward Nunes; Chrysovalantis Stafylis; Catherine Stanger; Elizabeth Saunders; Geetha Subramaniam; Sean Young Journal: J Subst Abuse Treat Date: 2020-03
Authors: Julie E Richards; Sarah D Hohl; Courtney D Segal; David C Grossman; Amy K Lee; Ursula Whiteside; Casey Luce; Evette J Ludman; Greg Simon; Robert B Penfold; Emily C Williams Journal: Psychiatr Serv Date: 2021-05-04 Impact factor: 4.157
Authors: Rachel L Bachrach; Matthew Chinman; Keri L Rodriguez; Maria K Mor; Kevin L Kraemer; Cécile E Garfunkel; Emily C Williams Journal: Addict Sci Clin Pract Date: 2022-03-14
Authors: Joseph E Glass; Theresa E Matson; Catherine Lim; Andrea L Hartzler; Kilian Kimbel; Amy K Lee; Tara Beatty; Rebecca Parrish; Ryan M Caldeiro; Angela Garza McWethy; Geoffrey M Curran; Katharine A Bradley Journal: J Med Internet Res Date: 2021-07-06 Impact factor: 5.428